| Wu, Yan |
NCT05463965: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 605 | RoW | QM1114-DP, OnabotulinumtoxinA, Placebo | Galderma R&D | Moderate to Severe Glabellar Lines | 01/23 | 06/23 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT06499688: A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 529 | RoW | Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA, Placebo | Chongqing Claruvis Pharmaceutical Co., Ltd. | Moderate to Severe Glabellar Lines | 03/24 | 05/24 | | |
NCT06583486: A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Active, not recruiting | 3 | 488 | RoW | Rcombinant botulinum neurotoxin type A for injection (YY001) | Chongqing Claruvis Pharmaceutical Co., Ltd. | Moderate to Severe Glabellar Lines | 08/25 | 08/25 | | |
NCT06585696: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101) |
|
|
| Recruiting | 3 | 554 | RoW | CU-20101 treatment for Moderate to Severe Glabellar Striae | Cutia Therapeutics（Wuxi）Co.,Ltd | Glabellar Frown Lines | 03/26 | 05/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
AK3280-2002, NCT05424887: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | 2 | 105 | RoW | AK3280, Placebo | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Idiopathic Pulmonary Fibrosis | 07/24 | 10/24 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 09/24 | 03/25 | | |
NCT05434897: A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | AK3280 Cream, AK3287, Placebo cream | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Hypertrophic Scar | 07/23 | 11/23 | | |
NCT04861766: Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults |
|
|
| Completed | N/A | 390 | RoW | STYLAGE® L, Active Comparator | Laboratoires Vivacy | Aging, Skin Wrinkling | 08/22 | 03/23 | | |
NCT05009381: Effectiveness and Safety of STYLAGE® XXL for Chin Augmentation in Chinese Adults |
|
|
| Completed | N/A | 174 | RoW | Stylage XXL at enrollment, Stylage XXL at Month 6 | Laboratoires Vivacy | Esthetic | 10/22 | 08/23 | | |
| Recruiting | N/A | 30000 | RoW | | Beijing Jishuitan Hospital, Chinese PLA General Hospital, Ruijin Hospital, Huashan Hospital, Henan Provincial People's Hospital, The Affiliated Hospital Of Guizhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital Xi'an Jiaotong University, The renmin hospital of wuhan university, Nanjing BenQ Hospital, China-Japan Friendship Hospital, xinan hospital, Wu Hu Yijishan hospital, The fifth affiliated hospital of zhong shan university | Osteoporosis, Obesity, Liver Steatoses | 06/23 | 12/23 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
| Xu, Ping |
| Recruiting | N/A | 10000 | RoW | Coronary angiography, CT angiography of aorta, CTA, CT angiography of pulmonary arteries., Electrocardiogram, ECG, Cardiac Troponin, Biomarkers of myocardial injury | West China Hospital | Chest Pain, Acute Aortic Dissection, Pulmonary Embolism, Acute Myocardial Infarction Type 1, Acute Coronary Syndrome | 10/21 | 10/22 | | |
EHCONSGDMC, NCT05911893: the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children |
|
|
| Not yet recruiting | N/A | 800 | RoW | high caloric oral nutritional supplements, high-energy total nutrition formula, nutritional education, dietary guidance | Children's Hospital of Chongqing Medical University, Anhui Provincial Children's Hospital, Baoji Maternity and Child Healthcare Hospital, Chengdu Women's and Children's Central Hospital, Guiyang Maternity and Child Health Care Hospital, Guangzhou Women and Children's Medical Center, Hunan Children's Hospital, Jiangxi Maternal and Child Health Hospital, Kunming Children's Hospital, Nanjing Maternity and Child Health Care Hospital, Children's Hospital of The Capital Institute of Pediatrics, Xianyang Children's Hospital, Nestle Health Science | Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition | 02/25 | 06/25 | | |
NCT04912401: the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis |
|
|
| Recruiting | N/A | 100 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis, Etanercept | 12/25 | 12/25 | | |
| Contact, See Central |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
| Completed | 2 | 342 | Japan | VN-0200 | Daiichi Sankyo | Respiratory Syncytial Virus Infections | 04/23 | 02/24 | | |
| Recruiting | 2 | 400 | Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan |
|
|
| Active, not recruiting | 2 | 21 | Japan | Pexidartinib, TURALIO™, PLX3397 | Daiichi Sankyo Co., Ltd. | Tenosynovial Giant Cell Tumor | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | US, RoW | Q702, Pembrolizumab, KEYTRUDA® | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer | 10/25 | 06/26 | | |
| Recruiting | 1/2 | 130 | US, RoW | Q901, KEYTRUDA® (pembrolizumab) | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Advanced Cancer, Metastatic Cancer | 12/25 | 08/26 | | |
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor |
|
|
| Active, not recruiting | 1 | 78 | US | Q702 | Qurient Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Cancer | 12/24 | 02/25 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 40 | Canada, Japan, US | DS-1055a | Daiichi Sankyo Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Solid Tumor | 06/25 | 06/25 | | |
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 280 | Japan, US, RoW | HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 06/25 | 02/26 | | |
| Recruiting | 1 | 80 | Japan | DS-1471a | Daiichi Sankyo Co., Ltd. | Advanced Solid Tumor | 06/27 | 06/27 | | |
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 225 | US | Archival tissue specimen and immunohistochemistry staining | Daiichi Sankyo, Inc. | Non-small Cell Lung Cancer | 04/23 | 04/23 | | |
| miao, jidong |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 3 | 270 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
| You, Wei |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). |
|
|
| Active, not recruiting | 3 | 270 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Han, Dengjun |
NCT05405439: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 39 | RoW | TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Castration-resistant Prostate Cancer | 07/23 | 07/23 | | |
| Chen, YunBo |
| Recruiting | N/A | 1332 | RoW | The lying flat (0°-10°) head position for 72 hours, The The head elevation (30°-40°) position for 72 hours | Zhengzhou Yuan | Stroke, Acute, Endovascular Therapy | 11/25 | 04/26 | | |
| cai, Ruifang |
DBS OCD, NCT06542224: Identifying Local Field Potential Biomarkers for Obsessive-compulsive Disorder Treatment With Deep Brain Stimulation |
|
|
| Recruiting | N/A | 16 | RoW | Deep Brain stimulation | West China Hospital, Beijing Pins Medical Co., Ltd | Obsessive-Compulsive Disorder | 07/26 | 12/26 | | |
